Xenetic Biosciences, Inc.
NASDAQ Capital MarketTotal Valuation
Xenetic Biosciences, Inc. carries a market capitalization of 5.62M, placing it among publicly traded companies globally. Its enterprise value stands at -6.47M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.62M |
| Enterprise Value | -6.47M |
Share Statistics
Xenetic Biosciences, Inc. currently has 2.29M shares outstanding.
| Shares Outstanding | 2.29M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Xenetic Biosciences, Inc. maintains a current ratio of 7.43, meaning it holds 7.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 7.43 |
| Quick Ratio | 7.23 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -47.05 |
| Return on Assets (ROA) | -40.17 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Xenetic Biosciences, Inc.'s stock has gained approximately 69.6325% over the past 52 weeks. The 50-day moving average sits at 12.44, while the 200-day moving average is 9.05.
| Beta (5Y) | N/A |
| 52-Week Price Change | 69.6325% |
| 50-Day Moving Average | 12.44 |
| 200-Day Moving Average | 9.05 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -2.64M, while operating income came in at -2.64M.
| Revenue | 3.26M |
| Gross Profit | N/A |
| Operating Income | -2.64M |
| Pretax Income | -2.48M |
| Net Income | -2.48M |
| EBITDA | -2.64M |
| EBIT | -2.64M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Total book value stands at 6.07M, with working capital of 5.76M providing operational flexibility.
| Cash & Cash Equivalents | 6.47M |
| Total Debt | N/A |
| Net Debt | -6.47M |
| Equity (Book Value) | 6.07M |
| Book Value Per Share | 2.65 |
| Working Capital | 5.76M |
Cash Flow
Xenetic Biosciences, Inc. produced -2.31M in operating cash flow over the past twelve months.
| Operating Cash Flow | -2.31M |
| Capital Expenditures | N/A |
| Free Cash Flow | -2.31M |
| FCF Per Share | N/A |
Margins
Xenetic Biosciences, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -81.01 and net profit margin of -75.91 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -81.01 |
| Pretax Margin | -75.91 |
| Profit Margin | -75.91 |
| EBITDA Margin | -81.01 |
Scores
Xenetic Biosciences, Inc. posts an Altman Z-Score of -40.23, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -40.23 |